Key result
ACE inhibitors maintain end-organ protection despite a narrowing outcomes gap with ARBs.
Why the study?
The concept of class effect for ACE inhibitors is confused and lacks a standardized definition, prompting a review of their use and effects.
ACE inhibitors remain a well-established class for antihypertensive therapy and end-organ protection, despite ongoing debates regarding class effects.
Supports ACE inhibitor preference in hypertension; leaves open whether ARBs now match end-organ protection across populations.
The angiotensin-converting enzyme (ACE) inhibitor drug class is one with considerable staying power. ACE inhibitors are not only well established antihypertensive agents but also are compounds that fairly regularly provide end-organ protection. Several of the ACE inhibitors are entangled in an active debate regarding class effect. Class effect for ACE inhibitors is a hopelessly confused term because its definition is not standardized and is subject to interpretation that in many cases is self-serving. For the most part, ACE inhibitor side effects are readily identifiable, and management strategies put in place can be logical and sequential. The future of this drug class remains bright. Other drug classes, such as angiotensin receptor blockers, have narrowed-but not entirely closed-the outcomes gap that exists between these two drug classes.
No takes yet. Share an insight, caveat, or question.
Domenic A. Sica (2005) reported a review. Angiotensin-converting enzyme (ACE) inhibitors vs. Angiotensin receptor blockers was evaluated. ACE inhibitors remain well-established antihypertensive agents that provide end-organ protection, though their outcomes gap with angiotensin receptor blockers has narrowed.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: